Mayo Clinic study finds blood test may predict Alzheimer's risk years in advance

A new study suggests a p-tau217 blood test could identify cognitive decline risk within five to 10 years, offering a less invasive alternative to PET scans.

A Mayo Clinic study published in JAMA Neurology indicates that a blood test detecting a protein linked to Alzheimer's disease may predict cognitive decline in older adults within five to 10 years. The test measures levels of phosphorylated tau 217 (p-tau217), which can reveal brain pathology through a simple blood sample. This method could be more scalable and less invasive than using PET scans to measure amyloid burden.

Researchers analyzed 2,178 cognitively unimpaired adults between the ages of 60 and 90. Participants were drawn from the Alzheimer's Disease Neuroimaging Initiative and the Mayo Clinic Study of Aging. The study accounted for gender, age, and the presence of the APOE ε4 genetic variant.

While the APOE ε4 variant showed a modest association with risk, older age was linked to higher risk levels. For instance, an 85-year-old with elevated p-tau217 levels faced a 37% estimated five-year risk of mild cognitive impairment, whereas a 65-year-old with the same levels had a 6% risk.

Clifford Jack Jr., a Mayo Clinic neuroradiologist and senior author, noted that many elderly people with lower levels of brain pathology never develop symptoms.

The clinical utility of the test could increase if effective preventive treatments are developed to delay or prevent decline. Alicia Algeciras-Schimnich, Ph.D., a Mayo Clinic researcher, said the goal is to provide personalized risk estimates rather than just reporting if a test is positive or negative for amyloid pathology.

Additionally, because the risk estimates were developed using the Mayo Clinic Study of Aging in southeast Minnesota, the findings must be replicated in other populations to ensure they represent the entire United States.

Key facts

  • A blood test for p-tau217 may predict cognitive decline within five to 10 years.
  • The study included 2,178 cognitively unimpaired adults aged 60 to 90.
  • An 85-year-old with elevated p-tau217 has a 37% five-year risk of mild cognitive impairment, compared to 6% for a 65-year-old.

Three perspectives

Neutral

A Mayo Clinic study found that a blood test measuring p-tau217 levels can help predict the risk of cognitive decline in older adults over the next five to 10 years.

Positive

The blood test offers a potentially more scalable and less invasive option for measuring amyloid burden than PET scans.

Negative

The risk prediction model is not currently ready for routine screening because there are no approved treatments for asymptomatic patients.

Your week in news, every Wednesday

The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.

Choose your news coverage

Please choose and confirm your coverage.

Next storyResearchers use pink noise to increase brain waste clearance during sleep

All sections

Edition